Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

SBC Medical Group Holdings (SBC) EBIT (2023 - 2025)

SBC Medical Group Holdings filings provide 3 years of EBIT readings, the most recent being $12.8 million for Q4 2025.

  • On a quarterly basis, EBIT rose 172.36% to $12.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.5 million, a 4.01% decrease, with the full-year FY2025 number at $67.5 million, down 4.01% from a year prior.
  • EBIT hit $12.8 million in Q4 2025 for SBC Medical Group Holdings, down from $15.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $27.3 million in Q2 2024 to a low of -$473374.0 in Q2 2023.
  • Median EBIT over the past 3 years was $15.2 million (2025), compared with a mean of $15.1 million.
  • The widest YoY moves for EBIT: up 6397.1% in 2024, down 80.33% in 2024.
  • SBC Medical Group Holdings' EBIT stood at $24.0 million in 2023, then tumbled by 80.33% to $4.7 million in 2024, then surged by 172.36% to $12.8 million in 2025.
  • The last three reported values for EBIT were $12.8 million (Q4 2025), $15.9 million (Q3 2025), and $14.6 million (Q2 2025) per Business Quant data.